title: Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.
abstract: BACKGROUND
  Amyotrophic lateral sclerosis (ALS) is the most serious form of degenerative motor neuron disease in adults, characterized by upper and lower motor neuron degeneration, skeletal muscle atrophy, paralysis, and death. High prevalence of malnutrition and weight loss adversely affect quality of life. Moreover, two thirds of patients develop a hypermetabolism of unknown cause, leading to increased resting energy expenditure. Inasmuch as lipids are the major source of energy for muscles, we determined the status of lipids in a population of patients with ALS and investigated whether lipid contents may have an impact on disease progression and survival.
  
  
  METHODS
  Blood concentrations of triglycerides, cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were measured in a cohort of 369 patients with ALS and compared to a control group of 286 healthy subjects. Postmortem histologic examination was performed on liver specimens from 59 other patients with ALS and 16 patients with Parkinson disease (PD).
  
  
  RESULTS
  The frequency of hyperlipidemia, as revealed by increased plasma levels of total cholesterol or LDL, was twofold higher in patients with ALS than in control subjects. As a result, steatosis of the liver was more pronounced in patients with ALS than in patients with PD. Correlation studies demonstrated that bearing an abnormally elevated LDL/HDL ratio significantly increased survival by more than 12 months.
  
  
  CONCLUSIONS
  Hyperlipidemia is a significant prognostic factor for survival of patients with amyotrophic lateral sclerosis. This finding highlights the importance of nutritional intervention strategies on disease progression and claims our attention when treating these patients with lipid-lowering drugs.
authors.affiliation: Fédération des Maladies du Système Nerveux, Centre référent maladie rare SLA, Hôpital de la Pitié-Salpêtrière, 47-83, Boulevard de l'Hôpital, 75651 Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Dupuis
authors.forename: P
authors.initials: P
authors.lastname: Corcia
authors.forename: A
authors.initials: A
authors.lastname: Fergani
authors.forename: J-L
authors.initials: JL
authors.lastname: Gonzalez De Aguilar
authors.forename: D
authors.initials: D
authors.lastname: Bonnefont-Rousselot
authors.forename: R
authors.initials: R
authors.lastname: Bittar
authors.forename: D
authors.initials: D
authors.lastname: Seilhean
authors.forename: J-J
authors.initials: JJ
authors.lastname: Hauw
authors.forename: L
authors.initials: L
authors.lastname: Lacomblez
authors.forename: J-P
authors.initials: JP
authors.lastname: Loeffler
authors.forename: V
authors.initials: V
authors.lastname: Meininger
mesh_terms: D000328:Adult; D000368:Aged; D000690:Amyotrophic Lateral Sclerosis / Q000453:epidemiology* / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood; D015897:Comorbidity; D019610:Cytoprotection; D050171:Dyslipidemias / Q000453:epidemiology* / Q000378:metabolism* / Q000503:physiopathology; D005234:Fatty Liver / Q000453:epidemiology / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D050356:Lipid Metabolism; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000294:innervation / Q000378:metabolism / Q000473:pathology; D018529:Nutritional Support / Q000592:standards; D015995:Prevalence; D015996:Survival Rate; D015854:Up-Regulation / Q000502:physiology
chemical_list: D008077:Lipoproteins, LDL; D002784:Cholesterol